Robinhood Asset Management LLC Takes Position in AbbVie Inc. $ABBV

Robinhood Asset Management LLC purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 72,406 shares of the company’s stock, valued at approximately $18,220,000. AbbVie accounts for about 1.0% of Robinhood Asset Management LLC’s investment portfolio, making the stock its 17th biggest position.

Several other hedge funds have also made changes to their positions in ABBV. ACT Advisors LLC. increased its position in AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after buying an additional 41 shares during the period. Willner & Heller LLC boosted its holdings in shares of AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock valued at $1,472,000 after acquiring an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC grew its position in shares of AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after acquiring an additional 43 shares during the last quarter. Fielder Capital Group LLC grew its position in shares of AbbVie by 1.7% during the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after acquiring an additional 43 shares during the last quarter. Finally, Leslie Global Wealth LLC increased its holdings in shares of AbbVie by 1.5% in the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company’s stock worth $751,000 after acquiring an additional 44 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 1.3%

Shares of AbbVie stock opened at $259.87 on Wednesday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The stock has a market cap of $459.14 billion, a PE ratio of 73.41, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. The company’s 50-day moving average price is $253.69 and its two-hundred day moving average price is $229.43.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ABBV shares. Canaccord Genuity Group lifted their price objective on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Barclays upped their target price on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Bank of America raised their price target on shares of AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $296.00 price target on shares of AbbVie in a report on Monday, August 3rd. Finally, BMO Capital Markets boosted their price objective on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $275.95.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics, an AbbVie company, launched SkinMedica Barrier Calming Cream and introduced HA 5 Hydra Collagen Facial Mist. Clinical testing reportedly showed a 30% reduction in skin dryness after two weeks, supporting AbbVie’s aesthetics and consumer-health growth strategy. SkinMedica Adds Barrier Calming Cream
• Positive Sentiment: AbbVie is cited as a potential beneficiary of an aging population, with its immunology portfolio positioned to capture long-term healthcare demand. Aging Population Drives Healthcare Growth
• Neutral Sentiment: AbbVie will present at the Wells Fargo Healthcare Conference on September 9. The event could provide updates on its pipeline, Humira replacement products and financial outlook, but no new information was announced yet. AbbVie Wells Fargo Healthcare Conference
• Neutral Sentiment: Investors are largely waiting for AbbVie’s next earnings update, leaving the stock without a major new near-term catalyst. AbbVie Stock Holds Steady
• Neutral Sentiment: New 340B-related court developments could affect drug-company pricing and reimbursement, but the article does not identify a specific immediate impact on AbbVie. 340B Court Updates
• Negative Sentiment: Erste Group Bank reduced its fiscal 2026 EPS estimate for AbbVie, signaling somewhat more cautious expectations for earnings growth. AbbVie FY2026 EPS Estimates Reduced

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.